BMLBMLKF 69 ROE % is 3.73% as of Mar. 2026, which is 57% below its 10-year median of 8.72. GuruFocus rates BMLKF with a GF Score™ of 69/100 and a GF Value™ of $26.78. The stock has 2 warning signs investors should review. Among 203 Medical Diagnostics & Research companies, BML ranks better than 68.47% on this metric.
ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. BML's annualized net income for the quarter that ended in Mar. 2026 was $30.0 Mil. BML's average Total Stockholders Equity over the quarter that ended in Mar. 2026 was $805.5 Mil. Therefore, BML's annualized ROE % for the quarter that ended in Mar. 2026 was 3.73%.
The historical rank and industry rank for BML's ROE % or its related term are showing as below:
BMLKF'
s ROE % Range Over the Past 10 Years
Min: 4.86 Med: 8.72 Max: 32.98
Current: 6.08
During the past 13 years, BML's highest ROE % was 32.98%. The lowest was 4.86%. And the median was 8.72%.
BMLKF's ROE % is ranked better than 68.47% of 203
companies
in the Medical Diagnostics & Research industry
Industry Median: -1.22
vs BMLKF: 6.08
BML (OTCPK:BMLKF) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
BML ROE % Related Terms
BML ROE % Historical Data
* Premium members only.
The historical data trend for BML's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, BML's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BML ROE % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, BML's ROE % distribution charts can be found below:
* The bar in red indicates where BML's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
BML (BMLKF) has a ROE % of 3.73% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on BML and its competitors. This is 57% below median its historical median of 8.72. Over the past decade, BML's ROE % has ranged from 4.86 to 32.98. According to the industry distribution chart, BML ranks #64 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 31.5%.
Is BML's ROE % too high?
BML's current ROE % of 3.73% is 57% below median its 10-year median of 8.72. Over the past 10 years, this metric has ranged from a low of 4.86 to a high of 32.98. Based on the distribution chart, BML ranks #64 out of 203 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, BML has a GF Score™ of 69/100, reflecting its overall financial health beyond just this single metric.
How does BML's ROE % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, BML ranks #64 out of 203 companies for ROE %. This puts BML in the upper half of its industry. Historically, BML's own ROE % has ranged from 4.86 to 32.98 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Diagnostics & Research company?
A good ROE % depends on the Medical Diagnostics & Research industry context. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on BML and its competitors. BML's current ROE % is 3.73%, which is 57% below median its own 10-year median of 8.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BML stock overvalued right now?
BML (BMLKF) has a current ROE % of 3.73%. The stock's GF Value™ is $26.78, compared to a current price of $25.21 — trading 5.9% below its estimated fair value. The current ROE % is 3.73%, which is 57% below median its 10-year median of 8.72. BML's overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For BML (BMLKF), the current ROE % is 3.73% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BML (BMLKF) Overvalued in 2026?
Based on GuruFocus' analysis, BML stock appears to be undervalued.
The current stock price of $25.21 is trading 5.9% below its estimated GF Value™ of $26.78.
Key valuation signals for BMLKF:
ROE %: 3.73% (57% below median its 10-year median of 8.72)
GF Value™: $26.78 vs. price of $25.21 (5.9% below fair value)
No single metric tells the full story. See the BMLKF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BML Inc provides laboratory testing services in Japan through a network of regional facilities. Its core clinical testing business provides a range of general and specialty laboratory tests, as well as microbiological tests that can be used for applications like food sanitation and environmental analysis. BML often uses automated systems to process and analyze these test samples. In addition to its clinical testing business, BML also has a medical information systems business and a genome-related business. The medical information systems business provides electronic medical charts and information systems that can be used in conjunction with its laboratory tests. The genome business provides gene analysis services.
69GF Score
Get the complete analysis for BMLKF
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BMLKF has been successfully added to your 
